JP2010509369A5 - - Google Patents

Download PDF

Info

Publication number
JP2010509369A5
JP2010509369A5 JP2009536520A JP2009536520A JP2010509369A5 JP 2010509369 A5 JP2010509369 A5 JP 2010509369A5 JP 2009536520 A JP2009536520 A JP 2009536520A JP 2009536520 A JP2009536520 A JP 2009536520A JP 2010509369 A5 JP2010509369 A5 JP 2010509369A5
Authority
JP
Japan
Prior art keywords
composition
vegf
antibody
use according
average thickness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009536520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509369A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/084320 external-priority patent/WO2008063932A2/en
Publication of JP2010509369A publication Critical patent/JP2010509369A/ja
Publication of JP2010509369A5 publication Critical patent/JP2010509369A5/ja
Pending legal-status Critical Current

Links

JP2009536520A 2006-11-10 2007-11-09 加齢黄斑変性症を処置するための方法 Pending JP2010509369A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86538006P 2006-11-10 2006-11-10
PCT/US2007/084320 WO2008063932A2 (en) 2006-11-10 2007-11-09 Method for treating age-related macular degeneration

Publications (2)

Publication Number Publication Date
JP2010509369A JP2010509369A (ja) 2010-03-25
JP2010509369A5 true JP2010509369A5 (enExample) 2010-12-02

Family

ID=39323041

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009536520A Pending JP2010509369A (ja) 2006-11-10 2007-11-09 加齢黄斑変性症を処置するための方法

Country Status (6)

Country Link
US (2) US20100111963A1 (enExample)
EP (1) EP2089059A2 (enExample)
JP (1) JP2010509369A (enExample)
AU (1) AU2007323925A1 (enExample)
CA (1) CA2666709A1 (enExample)
WO (1) WO2008063932A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52539B (sr) * 2004-10-21 2013-04-30 Genentech Inc. Metod za tretiranje intraokularnih neovaskularnih bolesti
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
HUE032894T2 (hu) 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
AU2009269149B2 (en) * 2008-06-30 2016-03-17 Mesoblast, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
JP5606438B2 (ja) 2008-07-23 2014-10-15 エフ．ホフマン−ラ ロシュ アーゲー 抗血管新生療法を受容可能な被験体の同定
AU2011206104A1 (en) * 2010-01-14 2012-07-12 Nagoya City University Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
EA022873B1 (ru) * 2010-10-27 2016-03-31 Новартис Аг Применение ингибитора vegf-r2 для лечения офтальмологического сосудистого заболевания
KR20200077622A (ko) 2011-01-13 2020-06-30 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
EP2671589A4 (en) * 2011-02-02 2014-11-19 Public Univ Corp Nagoya City Univ MEDICAMENT FOR PREVENTING OR TREATING DISEASES RELATED TO INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMEABILITY
WO2014031429A2 (en) * 2012-08-21 2014-02-27 Opko Pharmaceuticals, Llc Liposome formulations
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
AU2014274703B2 (en) * 2013-06-07 2019-07-04 The Johns Hopkins University A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
HK1220144A1 (zh) * 2013-10-08 2017-04-28 豪夫迈‧罗氏有限公司 N-(4-叔丁基-苄基)-3-氯-n-[2-(4-氯-3-乙基-苯基)-乙基]-2-氟-5-三氟甲基-苯甲酰胺用於治疗眼疾病的用途
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20180280414A1 (en) * 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
KR101880670B1 (ko) * 2015-11-06 2018-08-16 주식회사 모다이노칩 압력 센서를 구비하는 전자기기
CN114712497B (zh) 2015-12-03 2024-03-22 雷杰纳荣制药公司 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
WO2018051312A1 (en) * 2016-09-19 2018-03-22 Lupin Limited In-line filter for protein/peptide drug administration
IL274711B2 (en) 2017-11-30 2024-10-01 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
SG11202006255UA (en) 2018-02-02 2020-07-29 Univ Kyoto Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US190317A (en) * 1877-05-01 Improvement in barbers chairs
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
WO2003068801A2 (en) * 2002-02-11 2003-08-21 Genentech, Inc. Antibody variants with faster antigen association rates

Similar Documents

Publication Publication Date Title
JP2010509369A5 (enExample)
JP2022031772A5 (enExample)
JP2015528454A5 (enExample)
JP2014506321A5 (enExample)
JP2017534638A5 (enExample)
NZ598502A (en) Use of vegf antagonists in intraocular neovascular disease treatment
WO2007049017A3 (en) Agents that bind a target in pulmonary tissue for treating respiratory diseases
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
JP2016528202A5 (enExample)
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
JP2017528483A5 (enExample)
Rotenberg et al. Redefining the timing of surgery for obstructive sleep apnea in anatomically favorable patients
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
WO2017031319A1 (en) Noradrenergic drug treatment of obstructive sleep apnea
JP2012502103A5 (enExample)
JP2014503593A5 (enExample)
JP2018530574A5 (enExample)
JP2017523974A5 (enExample)
Singh et al. Pharmacological treatment of COPD: the devil is always in the detail
JP2022041802A5 (enExample)
JP2015522077A5 (enExample)
Custodio et al. Lack of clinically relevant effect of bictegravir (BIC, B) on metformin (MET) pharmacokinetics (PK) and pharmacodynamics (PD)
JP2017520562A5 (enExample)
Sockalingam et al. Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover study.
JP2019507786A5 (enExample)